|Clinical value of hematologic test in predicting tumor response to neoadjuvant chemotherapy with esophageal squamous cell carcinoma|
|Liu, Yinan1; Chen, Jinfeng1; Shao, Ningsheng2; Feng, Yuan1; Wang, Yuzhao1; Zhang, Lijian1|
|关键词||Esophageal Carcinoma Neoadjuvant Chemotherapy Hematologic Test|
|刊名||WORLD JOURNAL OF SURGICAL ONCOLOGY|
|WOS标题词||Science & Technology|
|类目[WOS]||Oncology ; Surgery|
|研究领域[WOS]||Oncology ; Surgery|
|关键词[WOS]||LOCALLY ADVANCED ESOPHAGEAL ; LONG-TERM SURVIVAL ; PHASE-II ; PREOPERATIVE CHEMORADIOTHERAPY ; GASTRIC-CANCER ; ADENOCARCINOMA ; SURGERY ; TRIAL ; OXALIPLATIN ; REGRESSION|
Background: To investigate the relationship between hematologic test results and the predictive effect of regression of esophageal cancer after neoadjuvant chemotherapy (NACT), we analyzed pre-NACT hematologic data and their relationship to tumor regression.
Methods: Thirty-eight consecutive patients with locally advanced squamous cell esophageal carcinoma who had undergone two cycles of paclitaxel/carboplatin NACT were enrolled. On the day prior to the first cycle of chemotherapy, hematologic tests, including routine blood test and biochemical examinations, were recorded. All patients were confirmed to have no history of hepatitis. Surgical resection was performed when clinical restaging showed effective regression. Histopathological examination was routinely performed to evaluate the postoperative effects of chemotherapy.
Results: After two cycles of NACT, tumor imaging evaluation showed that 27 of the 38 patients had CR and PR, including 25 patients who underwent radical esophagectomies. Six patients had stable disease and five patients had progressive disease. According to the hematologic test results before NACT, patients with higher white blood cell counts, lymphocyte percentages, mononuclear cell counts, neutrophilic granulocyte counts, and eosinophilic granulocyte counts and lower alanine aminotransferase (ALT) level had a significantly greater opportunity for an effective response.
Conclusion: Basal host immunologic function and hepatic function are associated with tumor response to NACT in patients with esophageal cancer. These parameters may have a certain predictive efficacy on NACT for esophageal squamous cell carcinoma.
|作者单位||1.Peking Univ, Canc Hosp & Inst, Dept Thorac Surg 2, Minist Educ,Key Lab Carcinogenesis & Translat Res, Beijing 100142, Peoples R China|
2.Beijing Inst Basic Med Sci, Dept Biochem & Mol Biol, Beijing 100850, Peoples R China
|Liu, Yinan,Chen, Jinfeng,Shao, Ningsheng,et al. Clinical value of hematologic test in predicting tumor response to neoadjuvant chemotherapy with esophageal squamous cell carcinoma[J]. WORLD JOURNAL OF SURGICAL ONCOLOGY,2014,12.|
|APA||Liu, Yinan,Chen, Jinfeng,Shao, Ningsheng,Feng, Yuan,Wang, Yuzhao,&Zhang, Lijian.(2014).Clinical value of hematologic test in predicting tumor response to neoadjuvant chemotherapy with esophageal squamous cell carcinoma.WORLD JOURNAL OF SURGICAL ONCOLOGY,12.|
|MLA||Liu, Yinan,et al."Clinical value of hematologic test in predicting tumor response to neoadjuvant chemotherapy with esophageal squamous cell carcinoma".WORLD JOURNAL OF SURGICAL ONCOLOGY 12(2014).|